Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
- 1 June 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 20 (6), 827-836
- https://doi.org/10.1016/s1470-2045(19)30088-9
Abstract
No abstract availableKeywords
Funding Information
- Daiichi Sankyo Europe
This publication has 27 references indexed in Scilit:
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancerGastric Cancer, 2014
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III StudyJournal of Clinical Oncology, 2014
- Consensus statement for the diagnosis and treatment of drug-induced lung injuriesRespiratory Investigation, 2013
- HER2 testing in gastric cancer: a practical approachLaboratory Investigation, 2012
- Pooled analysis of cardiac safety in patients with cancer treated with pertuzumabAnnals of Oncology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) TrialJournal of Clinical Oncology, 2010
- Life-threatening interstitial lung disease associated with trastuzumab: case reportBreast Cancer Research and Treatment, 2008
- Pulmonary toxicity from novel antineoplastic agentsAnnals of Oncology, 2005